NCT01910129终止不适用
A Randomized, Multi-center, Double-blind, Parallel, Crossover Study of a Non-invasive Neurostimulation to the Vagus Nerve With the gammaCore Device for the Reduction in Frequency of Seizures Associated With Epilepsy.
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 13
- 试验地点
- 2
- 主要终点
- Frequency of Seizures
研究概览
简要总结
The purpose of this study is to see the effects of non-invasive vagal nerve stimulation for the reduction in frequency of seizure associated with epilepsy in subjects 18 or older.
详细描述
The purpose of the study is to determine the effects of non-invasive vagus nerve stimulation for the reduction in frequency of seizure associated with epilepsy in subjects 18 or older. Subjects will record 4 weeks of baseline seizure activity before being randomized for a period of 8 weeks to receive and active treatment to an active-sham treatment. All subjects will then receive another 8 weeks of active treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient is diagnosed with epilepsy with; primary generalized tonic-clonic or partial complex or simple complex or focal onset seizures, with or without secondary generalization.
- •The patient's present antiepileptic drug (AED) therapy is ineffective or intolerable
- •The patient is receiving a stable dose of up to 2 oral AED medication(s) and is not expected to have any change in his/her baseline AED treatment during the treatment period.
- •The patient is having more than 2 recordable seizures a month.
排除标准
- •The patient has had status epilepticus within the last six months.
- •The patient has had epilepsy surgery or a VNS implant.
- •The patient has had a history or presence of seizures occurring only in clusters (too frequently or indistinctly separated to be reliably counted).
- •The patient has had 4 weeks continuous seizure freedom last 2 months.
- •The patient has psychogenic non-epileptic seizures (PNES) seizures.
- •The patient has a concomitant progressive CNS disease including progressive myoclonus epilepsy.
- •The patient has a significant history of cardiac, renal, neurologic (other than epilepsy), psychiatric, oncologic, endocrinologic, metabolic, or hepatic disease, which would adversely affect their participation in this study.
- •The patient has had an episode of status epilepticus within 4 weeks of Screening.
- •Has a lesion (including lymphadenopathy), dysaesthesia, previous surgery or abnormal anatomy at the GammaCore treatment site.
- •Has known or suspected severe atherosclerotic cardiovascular disease, severe carotid artery disease (e.g. bruits or history of TIA or CVA), congestive heart failure (CHF), known severe coronary artery disease or recent myocardial infarction.
- •Has an abnormal baseline ECG (e.g. second and third degree heart block, atrial fibrillation, atrial flutter, recent history of ventricular tachycardia or ventricular fibrillation, or clinically significant premature ventricular contraction).
- •Has had a previous bilateral, right, or left cervical vagotomy.
- •Has uncontrolled high blood pressure.
- •Is currently implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.
- •Has a history of carotid endarterectomy or vascular neck surgery on the right side.
- •Has been implanted with metal cervical spine hardware or has a metallic implant near the GammaCore stimulation site.
- •Has a recent or repeated history of syncope.
- •Has a known history or suspicion of substance abuse or addiction.
- •In the opinion of the investigator/research staff the subject is incapable of operating the GammaCore device as intended and performing the data collection procedures.
- •Is pregnant, nursing, thinking of becoming pregnant in the next 9 months, or of childbearing years and is unwilling to use an accepted form of birth control.
研究组 & 干预措施
gammaCore
Active Comparator
Active stimulation treatment
干预措施: gammaCore (Device)
sham gammaCore
Placebo Comparator
Inactive stimulation treatment
干预措施: gammaCore (Device)
结局指标
主要结局
Frequency of Seizures
时间窗: 16 weeks
The seizure frequency was collected in the subject diary throughout Intervention 1/Phase 2 (8 weeks) and Intervention 2/Phase 3 (8 weeks).
次要结局
- Duration of Seizure(16 weeks)
- Severity of Seizure(16 weeks)
- Type of Adverse Events(16 weeks)
- Number of Seizure Free Days(16 weeks)
- Quality of Life in Epilepsy(16 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Use of taVNS for Painful Diabetic Neuropathy: 12-Week Randomized, Sham-Controlled TrialDiabetic NeuropathiesNeuropathic PainType2diabetesDiabetes MellitusNCT06292962Saima Abass Tahammal185
已完成
不适用
Non-invasive Neurostimulation of the Vagus Nerve for the Treatment of Cluster HeadacheCluster HeadacheNCT01792817ElectroCore INC150
已完成
不适用
Non-Invasive Neurostimulation for the Prevention of Chronic MigraineChronic MigraineNCT01667250ElectroCore INC59
撤回
不适用
Non-Invasive Neurostimulation of the Vagus Nerve With the AlphaCore Device for the Relief of EIBAsthmaNCT01923272ElectroCore INC
招募中
Unknown
The effect of rehabilitation and non-invasive vagus nerve stimulation on the treatment of vestibular migrainevestibular migraine.MigraineIRCT20160131026279N5Tehran University of Medical Sciences28